Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab intravitreal therapy for age-related macular degeneration
2007-001418-17Phase 2Active
- Sponsor
- Azienda Ospedaliero-Universitaria di Padova
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of bevacizumab in age-related macular degeneration (AMD) (2 arms), sponsored by Azienda Ospedaliero-Universitaria di Padova. Primary endpoint: Primary efficacy of intravitreal bevacizumab. Started Mar 2007; status: active.
02
Drugs
bevacizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2007-001418-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001418-17.